Barclays PLC Has $979,000 Stake in Savara Inc (NASDAQ:SVRA)

Barclays PLC lifted its stake in Savara Inc (NASDAQ:SVRA) by 217.5% in the third quarter, HoldingsChannel.com reports. The firm owned 231,005 shares of the company’s stock after purchasing an additional 158,244 shares during the quarter. Barclays PLC’s holdings in Savara were worth $979,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its position in Savara by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock valued at $1,162,000 after purchasing an additional 32,142 shares during the period. Principal Financial Group Inc. lifted its holdings in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares during the period. Victory Capital Management Inc. acquired a new position in Savara in the second quarter valued at approximately $527,000. Choreo LLC bought a new position in Savara in the second quarter valued at approximately $59,000. Finally, XTX Topco Ltd grew its holdings in Savara by 289.1% during the 2nd quarter. XTX Topco Ltd now owns 41,059 shares of the company’s stock worth $165,000 after acquiring an additional 30,508 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

SVRA has been the topic of a number of analyst reports. HC Wainwright cut their price target on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company initiated coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. Finally, Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.86.

Insider Transactions at Savara

In other news, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares in the company, valued at $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by insiders.

Savara Stock Down 2.5 %

Shares of Savara stock opened at $2.72 on Wednesday. The company has a market capitalization of $466.80 million, a P/E ratio of -6.33 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business has a 50-day moving average of $3.29 and a two-hundred day moving average of $3.88. Savara Inc has a 1 year low of $2.60 and a 1 year high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, equities analysts predict that Savara Inc will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.